Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort Study
Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort Study
Evaluation of clinical outcome and economical aspects in the treatment of patients with peritoneal carcinomatosis.
Peritoneal carcinomatosis is a dooming finding with no hope for cure and a steadily decrease in quality of life. Cytoreductive surgery with intraperitoneal chemotherapy (CRS HIPEC) offers a small but proven chance for cure. The implementation of a CRS HIPEC and PIPAC programme in a Swiss tertiary care hospital is evaluated.
When a patient is deemed non resectable, pressurized intraperitoneal aerosol chemotherapy (PIPAC) administered laparoscopically may confer effective palliation.
Inclusion Criteria:
Exclusion Criteria:
Michel.Adamina@ksw.ch+41522663634